Magnetic resonance imaging (MRI) is a collection of very sensitive and versatile techniques for detecting multiple sclerosis (MS) related damage in the central nervous system. Each technique is characterised by a particular combination of sensitivity, tissue and pathological specificity, and technical requirements that enable diverse aspects of MS to be explored.
MRI techniques also offer the possibility of quantitatively assessing the effects of therapeutic interventions, and to correlate these effects to clinical outcomes. Of special interest are newer MR techniques that correlate more strongly with disability than gadolinium-enhancement and T2 lesion load, and this review focuses on T1 hypointense lesions, MR spectroscopy, and brain atrophy as surrogate markers of axonal loss, and their application in randomised clinical trials.
Several disease-modifying therapies appear to have differential effects on inflammation, demyelination and axonal loss as judged by MRI, illustrating the unique capability of MRI to interrogate the pathophysiology of MS. At the same time it illustrates the difficulties in understanding the mechanisms leading to axonal loss and persistent clinical deficit.
ArnoldDLRiessGTMatthewsPMFrancisGSCollinsDLWolfsonCAntelJP (1994) Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol36:76–82.
2.
BakshiRBenedictRHBermelRAJacobsL (2001) Regional brain atrophy is associated with physical disability in multiple sclerosis: semiquantitative magnetic resonance imaging and relationship to clinical findings. J Neuroimaging11:129–136.
3.
BakshiRCzarneckiDShaikhZAPrioreRLJanardhanVKaliszkyZKinkelPR (2000) Brain MRI lesions and atrophy are related to depression in multiple sclerosis. Neuroreport11: 1153–1158.
4.
BarkhofF (2002) The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol15:239–245.
5.
BarkhofFvan WaesbergheJHFilippiMYousryTMillerDHHahnDThompsonAJKapposLBrexPPozzilliCPolmanCH (2001) T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. Brain124:1396–1402.
6.
BermelRABakshiRTjoaCPuliSRJacobsL (2002) Bicaudate ratio as a magnetic resonance imaging marker of brain atrophy in multiple sclerosis. Arch Neurol59:275–280.
7.
BjartmarCKiddGMorkSRudickRTrappBD (2000) Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol48:893–901.
8.
BrexPACiccarelliOO'RiordanJISailerMThompsonAJMillerDH (2002) A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med346: 158–164.
9.
ChardDTGriffinCMMcLeanMAKapellerPKapoorRThompsonAJMillerDH (2002) Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain125:2342–2352.
10.
ChristodoulouCKruppLBLiangZHuangWMelvillePRoqueCScherlWFMorganTMacAllisterWSLiLTudoricaLALiXRochePPeysterR (2003) Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients. Neurology60:1793–1798.
11.
ColesAJWingMGMolyneuxPPaolilloADavieCMHaleGMillerDWaldmannHCompstonA (1999) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol46:296–304.
12.
ComiGIngleseMDe StefanoNSmithSBarkhofFDurelliL. (2002) Brain volume changes in patients at presentation with suspected multiple sclerosis: results from the ETOMS study. Lancet (in press)
13.
ComiGFilippiMWolinskyJS (2001) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol49:290–297.
14.
DautryCVaufreyFBrouilletEBizatNHenryPGCondeFBlochGHantrayeP (2000) Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3-nitropropionic acid. J Cereb Blood Flow Metab20:789–799.
15.
De StefanoNMatthewsPMFilippiMAgostaFDe LucaMBartolozziMLGuidiLGhezziAMontanariECifelliAFedericoASmithSM (2003) Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology60:1157–1162.
16.
FilippiMIannucciGTortorellaCMinicucciLHorsfieldMAColomboBSormaniMPComiG (1999) Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. Neurology52:588–594.
17.
FilippiMRoccaMA (2003) Disturbed function and plasticity in multiple sclerosis as gleaned from functional magnetic resonance imaging. Curr Opin Neurol16:275–282.
18.
FilippiMRovarisMRoccaMASormaniMPWolinskyJSComiG (2001) Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes”. Neurology57:731–733.
19.
FisherERudickRACutterGBaierMMillerDWeinstock-GuttmanBMassMKDoughertyDSSimonianNA (2000) Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler6:373–377.
20.
FisherERudickRASimonJHCutterGBaierMLeeJCMillerDWeinstock-GuttmanBMassMKDoughertyDSSimonianNA (2002) Eight-year follow-up study of brain atrophy in patients with MS. Neurology59:1412–1420.
21.
FuLWolfsonCWorsleyKJDe StefanoNCollinsDLNarayananSArnoldDL (1996) Statistics for investigation of multimodal MR imaging data and an application to multiple sclerosis patients. NMR Biomed9: 339–346.
22.
GiugniEPozzilliCBastianelloSGasperiniCPaolilloAKoudriavtsevaTFrontoniMFarinaDBozzaoL (1997) MRI measures and their relations with clinical disability in relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler3:221–225.
23.
GrimaudJBarkerGJWangLLaiMMacManusDGWebbSLThompsonAJMcDonaldWIToftsPSMillerDH (1999) Correlation of magnetic resonance imaging parameters with clinical disability in multiple sclerosis: a preliminary study. J Neurol246: 961–967.
24.
HohlfeldRKerschensteinerMStadelmannCLassmannHWekerleH (2000) The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. J Neuroimmunol107:161–166.
25.
JanardhanVBakshiR (2000) Quality of life and its relationship to brain lesions and atrophy on magnetic resonance images in 60 patients with multiple sclerosis. Arch Neurol57: 1485–1491.
26.
JonesCKRiddehoughALiDKBZhaoGJPatyDW (2001) MRI cerebral atrophy in relapsing-remitting MS: Results from the PRISMS trial. Neurol56:A379 (Abstract)
27.
KerschensteinerMStadelmannCDechantGWekerleHHohlfeldR (2003) Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol53:292–304.
28.
KoudriavtsevaTThompsonAJFiorelliMGasperiniCBastianelloSBozzaoAPaolilloAPisaniAGalganiSPozzilliC (1997) Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry62:285–287.
29.
LinXTenchCRTurnerBBlumhardtLDConstantinescuCS (2003) Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial. J Neurol Neurosurg Psychiatry74:1090–1094.
30.
McFarlandHF (2002) The emerging role of MRI in multiple sclerosis and the new diagnostic criteria. Mult Scler8:71–72.
31.
MillerDHBarkhofFFrankJAParkerGJThompsonAJ (2002) Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain125: 1676–1695.
32.
MolyneuxPDKapposLPolmanCPozzilliCBarkhofFFilippiMYousryTHahnDWagnerKGhaziMBeckmannKDahlkeFLosseffNBarkerGJThompsonAJMillerDH (2000) The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain123:2256–2263.
33.
NarayananSDe StefanoNFrancisGSArnaoutelisRCaramanosZCollinsDLPelletierDArnasonBGWAntelJPArnoldDL (2001) Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol248:979–986.
34.
O'RiordanJIGawneCMColesAWangLCompstonDAToftsPMillerDH (1998) T1 hypointense lesion load in secondary progressive multiple sclerosis: a comparison of pre versus post contrast loads and of manual versus semi automated threshold techniques for lesion segmentation. Mult Scler4:408–412.
35.
PaolilloABastianelloSFrontoniMGasperiniCGiugniECiccarelliOLuccichentiGCannoniSPozzilliC (1999) Magnetic resonance imaging outcome of new enhancing lesions in relapsing-remitting multiple sclerosis patients treated with interferon beta1a. J Neurol246:443–448.
36.
ParryACorkillRBlamireAMPalaceJNarayananSArnoldDStylesPMatthewsPM (2003) Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis. J Neurol250:171–178.
37.
PetersonJWBoLMorkSChangATrappBD (2001) Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol50:389–400.
38.
RovarisMComiGRoccaMAWolinskyJSFilippiM (2001) Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain124:1803–1812.
39.
RudickRAFisherELeeJCSimonJJacobsL (1999) Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology53:1698–1704.
40.
SailerMFischlBSalatDTempelmannCSchonfeldMABusaEBodammerNHeinzeHJDaleA (2003) Focal thinning of the cerebral cortex in multiple sclerosis. Brain126: 1734–1744.
41.
SarchielliPPresciuttiOTarducciRGobbiGAlbertiAPelliccioliGPOrlacchioAGallaiV (1998) 1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study. J Neurol Neurosurg Psychiatry64: 204–212.
42.
SimonJHLullJJacobsLDRudickRACookfairDLHerndonRMRichertJRSalazarAMSheederJMillerDMcCabeKSerraACampionMKFischerJSGoodkinDESimonianNLajaunieMWendeKMartens-DavidsonAKinkelRPMunschauerFEIII. (2000) A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group. Neurology55:185–192.
43.
TruyenLvan WaesbergheJHvan WalderveenMAvan OostenBWPolmanCHHommesORAderHJBarkhofF (1996) Accumulation of hypointense lesions (“black holes”) on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology47:1469–1476.
44.
TurnerBLinXCalmonGRobertsNBlumhardtLD (2003) Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years. Mult Scler9:21–27.
45.
van WalderveenMABarkhofFPouwelsPJvan SchijndelRAPolmanCHCastelijnsJA (1999) Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol46:79–87.
46.
ZivadinovRRudickRADe MasiRNasuelliDUkmarMPozzi-MucelliRSGropACazzatoGZorzonM (2001) Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology57: 1239–1247.
